These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 12197314)

  • 21. Cholesteryl ester transfer protein (CETP) increases postprandial triglyceridaemia and delays triacylglycerol plasma clearance in transgenic mice.
    Salerno AG; Patrício PR; Berti JA; Oliveira HC
    Biochem J; 2009 May; 419(3):629-34. PubMed ID: 19191759
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Liver microsomal triglyceride transfer protein is involved in hepatitis C liver steatosis.
    Mirandola S; Realdon S; Iqbal J; Gerotto M; Dal Pero F; Bortoletto G; Marcolongo M; Vario A; Datz C; Hussain MM; Alberti A
    Gastroenterology; 2006 May; 130(6):1661-9. PubMed ID: 16697730
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cholesteryl ester transfer protein (CETP) inhibition beyond raising high-density lipoprotein cholesterol levels: pathways by which modulation of CETP activity may alter atherogenesis.
    Klerkx AH; El Harchaoui K; van der Steeg WA; Boekholdt SM; Stroes ES; Kastelein JJ; Kuivenhoven JA
    Arterioscler Thromb Vasc Biol; 2006 Apr; 26(4):706-15. PubMed ID: 16439711
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Secretion of atherogenic risk factor apolipoprotein B-100 is increased by a potential mechanism of JNK/PKC-mediated insulin resistance in liver cells.
    Jin UH; Kang YJ; Chang YC; Kim CH
    J Cell Biochem; 2008 Feb; 103(3):908-19. PubMed ID: 17647275
    [TBL] [Abstract][Full Text] [Related]  

  • 25. HDL as a target in the treatment of atherosclerotic cardiovascular disease.
    Linsel-Nitschke P; Tall AR
    Nat Rev Drug Discov; 2005 Mar; 4(3):193-205. PubMed ID: 15738977
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Microsomal triglyceride transfer protein -493T variant reduces IDL plus LDL apoB production and the plasma concentration of large LDL particles.
    Lundahl B; Skoglund-Andersson C; Caslake M; Bedford D; Stewart P; Hamsten A; Packard CJ; Karpe F
    Am J Physiol Endocrinol Metab; 2006 Apr; 290(4):E739-45. PubMed ID: 16291571
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Possible involvement of enhanced intestinal microsomal triglyceride transfer protein (MTP) gene expression in acceleration of lipid absorption by a western-type diet in apolipoprotein E knockout mice.
    Ueshima K; Akihisa-Umeno H; Sawada M; Nagayoshi A; Ozaki T; Takakura S; Manda T; Mutoh S
    Life Sci; 2004 Nov; 76(2):179-90. PubMed ID: 15519363
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Therapeutic implications of cholesteryl ester transfer protein inhibitors in hyperlipidemia and low high-density lipoprotein-cholesterolemia.
    Inazu A; Mabuchi H
    Curr Opin Investig Drugs; 2003 Mar; 4(3):291-7. PubMed ID: 12735230
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identification of microsomal triglyceride transfer protein in intestinal brush-border membrane.
    Slight I; Bendayan M; Malo C; Delvin E; Lambert M; Levy E
    Exp Cell Res; 2004 Oct; 300(1):11-22. PubMed ID: 15383310
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Discovery of benzothiazole derivatives as efficacious and enterocyte-specific MTP inhibitors.
    Vu CB; Milne JC; Carney DP; Song J; Choy W; Lambert PD; Gagne DJ; Hirsch M; Cote A; Davis M; Lainez E; Meade N; Normington K; Jirousek MR; Perni RB
    Bioorg Med Chem Lett; 2009 Mar; 19(5):1416-20. PubMed ID: 19181526
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Where are we with high-density lipoprotein raising and inhibition of cholesteryl ester transfer for heart disease risk reduction?
    Schaefer EJ; Asztalos BF
    Curr Opin Cardiol; 2007 Jul; 22(4):373-8. PubMed ID: 17556892
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Statins and diabetes.
    Carmena R; Betteridge DJ
    Semin Vasc Med; 2004 Nov; 4(4):321-32. PubMed ID: 15861314
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Microsomal triglyceride transfer protein polymorphism (-493G/T) is associated with hepatic steatosis in patients with chronic hepatitis C.
    Mirandola S; Osterreicher CH; Marcolongo M; Datz C; Aigner E; Schlabrakowski A; Realdon S; Gerotto M; Alberti A; Stickel F
    Liver Int; 2009 Apr; 29(4):557-65. PubMed ID: 19018985
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Regulating microsomal triglyceride transfer protein with natural products for the treatment of hyperlipidaemia.
    Sabry MO; Sedeek MS; El-Sonbaty SM; Issa MY; El Zalabani SM
    Nat Prod Res; 2024 Jan; ():1-5. PubMed ID: 38178602
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Key issues for establishing a robotics laboratory in the pharmaceutical industry.
    Conder S
    J Automat Chem; 1994; 16(4):117-9. PubMed ID: 18924996
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Metabolic effects of digestible and partially indigestible cornstarch: a study in the absorptive and postabsorptive periods in healthy humans.
    Achour L; Flourié B; Briet F; Franchisseur C; Bornet F; Champ M; Rambaud JC; Messing B
    Am J Clin Nutr; 1997 Nov; 66(5):1151-9. PubMed ID: 9356532
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Microsomal transfer protein (MTP) inhibition-a novel approach to the treatment of homozygous hypercholesterolemia.
    Sirtori CR; Pavanello C; Bertolini S
    Ann Med; 2014 Nov; 46(7):464-74. PubMed ID: 24987866
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Acquired resistance to sunitinib in human renal cell carcinoma cells is mediated by constitutive activation of signal transduction pathways associated with tumour cell proliferation.
    Sakai I; Miyake H; Fujisawa M
    BJU Int; 2013 Jul; 112(2):E211-20. PubMed ID: 23305097
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Gene therapy for familial hypercholesterolemia.
    Van Craeyveld E; Jacobs F; Gordts SC; De Geest B
    Curr Pharm Des; 2011; 17(24):2575-91. PubMed ID: 21774774
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chronic rapamycin treatment causes glucose intolerance and hyperlipidemia by upregulating hepatic gluconeogenesis and impairing lipid deposition in adipose tissue.
    Houde VP; Brûlé S; Festuccia WT; Blanchard PG; Bellmann K; Deshaies Y; Marette A
    Diabetes; 2010 Jun; 59(6):1338-48. PubMed ID: 20299475
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.